TY - JOUR T1 - Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine JF - bioRxiv DO - 10.1101/2021.04.30.441559 SP - 2021.04.30.441559 AU - Gajanan Sapkal AU - Pragya D. Yadav AU - Raches Ella AU - Priya Abraham AU - Deepak Y. Patil AU - Nivedita Gupta AU - Samiran Panda AU - V. Krishna Mohan AU - Balram Bhargava Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/04/30/2021.04.30.441559.abstract N2 - The emergence of new SARS-CoV-2 variants has been a serious threat to the public health system and vaccination program. The variant of concerns have been the under investigation for their neutralizing potential against the currently available COVID-19 vaccines. Here, we have determined the neutralization efficacy of B.1.1.28.2 variant with the convalescent sera of individuals with natural infection and BBV152 vaccination. The two-dose vaccine regimen significantly boosted the IgG titer and neutralizing efficacy against both B.1.1.28.2 and D614G variants compared to that seen with natural infection. The study demonstrated 1.92 and 1.09 fold reductions in the neutralizing titer against B.1.1.28.2 variant in comparison with prototype D614G variant with sera of vaccine recipients and natural infection respectively.Competing Interest StatementThe authors have declared no competing interest. ER -